This article reviews some of the lessons learned by Columbia University in five years of managing or co-managing proof-of-concept center accelerators for grant-funded technologies in three industries: medical devices, diagnostics, and imaging; clean energy; and media.
TheraPten Biosciences Inc., a Canadian biotechnology company, has entered into an exclusive licensing agreement with Columbia University on two globally issued patent families covering PTEN-L, a naturally-occurring tumor suppressor protein.
Applied Therapeutics Inc., today announced the closing of its Series A financing round. The financing was led by Alexandria Venture Investments alongside E Squared Capital Management, Franklin Berger, ETP Global Fund and Syno Capital. Joel S.
Lin Bioscience and Columbia Technology Ventures announced that Lin Bioscience has licensed the intellectual property portfolio and development program for a promising first-in-class medication intended to slow or halt the progression of atrophic "Dry" Age-Related Macular Degeneration (AMD).
Fortress Biotech, Inc. announced the formation of a new subsidiary company, Caelum Biosciences, Inc., to advance the development of CAEL‐ 101 (11‐1F4) for the treatment of amyloid light chain (“AL”) amyloidosis.
Mannheim/Wetzlar, Germany. Leica Microsystems CMS GmbH has entered into an exclusive, worldwide licensing agreement with Columbia University in New York to commercialize SCAPE microscopy for Life Science applications.